Crewe Advisors LLC Alnylam Pharmaceuticals, Inc. Transaction History

Crewe Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$185.01 - $212.05 $4,810 - $5,513	-26 Reduced 96.3%	1 $0
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $4,201 - $5,417	-23 Reduced 46.0%	27 $5,000
Q4 2022 Feb 07, 2023	SELL	$185.53 - $241.31 $6,679 - $8,687	-36 Reduced 41.86%	50 $11,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $2,078 - $3,480	15 Added 21.13%	86 $17,000
Q2 2022 Aug 02, 2022	BUY	$120.42 - $169.29 $8,549 - $12,019	71 New	71 $10,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Crewe Advisors LLC with notifications on news.